Bivalirudin

Drug Profile

Bivalirudin

Alternative Names: Angiomax; Angiox; BG-8967; Hirulog-1

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer The Medicines Company
  • Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Peptide fragments; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 10 May 2017 SciClone Pharmaceuticals announces intention to submit NDA to US FDA in 2017
  • 21 Apr 2017 The Medicines Company terminates the phase III ENDOMAX trial for Thrombosis prevention (in patients undergoing peripheral endovascular interventions) in USA (IV) (NCT01913483)
  • 06 Mar 2017 SciClone anticipates approval of bivalirudin for Heparin-induced thrombocytopenia and thrombosis syndrome and Unstable angina pectoris in China in late 2017 or early 2018 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top